| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Atomoxetine HCl (formerly LY139603; LY-139603; Tomoxetine; Strattera; Tomoxetina; Tomoxetinum), the hydrochloride salt of Atomoxetine, is a potent and selective norepinephrine (NE) transporter/reuptate inhibitor that has been used for treating attention-deficit hyperactivity disorder (ADHD). It has a Ki of 5 nM for norepinephrine (NE) transporter/reuptate inhibition, and it has 290- and 15-fold lower affinity for human 5-HT and DA transporters, respectively. The treatment of ADHD with atomoxetine has received approval.
| Targets |
Norepinephrine (NE) transporter ( Ki = 5 nM ); 5-HT ( Ki = 77 nM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C17H22CLNO
|
|
|---|---|---|
| Molecular Weight |
291.82
|
|
| Exact Mass |
255.16
|
|
| Elemental Analysis |
C, 69.97; H, 7.60; Cl, 12.15; N, 4.80; O, 5.48
|
|
| CAS # |
82248-59-7
|
|
| Related CAS # |
Atomoxetine; 83015-26-3; Atomoxetine-d5 hydrochloride
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl
|
|
| InChi Key |
LUCXVPAZUDVVBT-UNTBIKODSA-N
|
|
| InChi Code |
InChI=1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1
|
|
| Chemical Name |
(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine;hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 8.33 mg/mL (28.54 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4268 mL | 17.1338 mL | 34.2677 mL | |
| 5 mM | 0.6854 mL | 3.4268 mL | 6.8535 mL | |
| 10 mM | 0.3427 mL | 1.7134 mL | 3.4268 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04565288 | Active Recruiting |
Drug: Atomoxetine Drug: Placebo |
Alcohol Use Disorder | Brown University | May 6, 2021 | Phase 2 |
| NCT04354103 | Recruiting | Drug: Atomoxetine | Tourette Syndrome | Poitiers University Hospital | May 31, 2022 | Phase 2 |
| NCT03919955 | Recruiting | Drug: Atomoxetine Drug: Oxybutynin |
Sleep Apnea | Brigham and Women's Hospital | September 3, 2019 | Phase 2 |
| NCT04216186 | Recruiting | Drug: Atomoxetine Drug: Coenzyme Q |
ADHD | Sherief Abd-Elsalam | November 1, 2018 | Phase 3 |
| NCT05550246 | Recruiting | Drug: Asimadoline Drug: Placebo |
Obstructive Sleep Apnea | Brigham and Women's Hospital | May 5, 2022 | Phase 1 Phase 2 |
 |
|---|
  |
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA